Best Practices for Highly Potent API (HPAPI) Development and Manufacturing
Original Air Date: Wednesday, July 18th, 11 am - 12pm
Drug product development for highly potent APIs (HPAPIs) can be challenging. Complications with the interface between operations in drug substance and drug product handling can result in increased program complexity and cost.
In this webcast, an API manufacturing expert will present and discuss best practices for developing and manufacturing highly potent compounds; infrastructure requirements that can facilitate development; and accelerated timelines to clinic and market.
Case studies will review the development, rapid scaling, and commercial production of HPAPI drug substance, as well as integrated containment requirements for particle engineering and drug product.
An API manufacturing expert will present and discuss
Speakers:
Philipp Künti, Head of Chemical Manufacturing Small Scale, Lonza Pharma & Biotech
Maurits Janssen, PhD, Senior Director, Head of Commercial Development, Lonza Pharma & Biotech
Please note that Lonza has updated its Privacy Policy. By visiting our website or using services provided by Lonza, you are accepting the practices described in the Privacy Policy.
We also use cookies on our websites. Cookies allow us to give you the best browsing experience and help us to understand how you use our site. You can disable cookies but parts of our website may not work. Please read our updated Cookies Policy for information about which cookies we use and the information we collect. By continuing to use this website, you agree that we may store and access cookies on your device.
By clicking "I Agree", you confirm that you are above the age of 16, that you have read and understood the Privacy Policy and the Cookies Policy, and that you agree to the collection, use and processing of your Personal Information by Lonza in accordance with said policies.